376 related articles for article (PubMed ID: 26161925)
21. Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone.
Traub F; Singh J; Dickson BC; Leung S; Mohankumar R; Blackstein ME; Razak AR; Griffin AM; Ferguson PC; Wunder JS
Eur J Cancer; 2016 May; 59():1-12. PubMed ID: 26990281
[TBL] [Abstract][Full Text] [Related]
22. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.
Federman N; Brien EW; Narasimhan V; Dry SM; Sodhi M; Chawla SP
Paediatr Drugs; 2014 Feb; 16(1):21-8. PubMed ID: 24114694
[TBL] [Abstract][Full Text] [Related]
23. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
24. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
25. Pathogenesis of Osteosclerotic Change Following Treatment with an Antibody Against RANKL for Giant Cell Tumour of the Bone.
Rosario M; Takeuchi A; Yamamoto N; Hayashi K; Miwa S; Higuchi T; Abe K; Taniguchi Y; Aiba H; Tanzawa Y; Murakami H; Tsuchiya H
Anticancer Res; 2017 Feb; 37(2):749-754. PubMed ID: 28179326
[TBL] [Abstract][Full Text] [Related]
26. RANKL, denosumab, and giant cell tumor of bone.
Thomas DM
Curr Opin Oncol; 2012 Jul; 24(4):397-403. PubMed ID: 22581354
[TBL] [Abstract][Full Text] [Related]
27. The clinical approach toward giant cell tumor of bone.
van der Heijden L; Dijkstra PD; van de Sande MA; Kroep JR; Nout RA; van Rijswijk CS; Bovée JV; Hogendoorn PC; Gelderblom H
Oncologist; 2014 May; 19(5):550-61. PubMed ID: 24718514
[TBL] [Abstract][Full Text] [Related]
28. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
29. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
Palmerini E; Chawla NS; Ferrari S; Sudan M; Picci P; Marchesi E; Leopardi MP; Syed I; Sankhala KK; Parthasarathy P; Mendanha WE; Pierini M; Paioli A; Chawla SP
Eur J Cancer; 2017 May; 76():118-124. PubMed ID: 28324746
[TBL] [Abstract][Full Text] [Related]
30. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
[TBL] [Abstract][Full Text] [Related]
31. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.
Thomas D; Henshaw R; Skubitz K; Chawla S; Staddon A; Blay JY; Roudier M; Smith J; Ye Z; Sohn W; Dansey R; Jun S
Lancet Oncol; 2010 Mar; 11(3):275-80. PubMed ID: 20149736
[TBL] [Abstract][Full Text] [Related]
32. Denosumab: Current Use in the Treatment of Primary Bone Tumors.
Savvidou OD; Bolia IK; Chloros GD; Papanastasiou J; Koutsouradis P; Papagelopoulos PJ
Orthopedics; 2017 Jul; 40(4):204-210. PubMed ID: 28732103
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of RANKL Expression in Osteocyte-like Differentiated Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment.
Noguchi T; Sakamoto A; Murotani Y; Murata K; Hirata M; Yamada Y; Toguchida J; Matsuda S
J Histochem Cytochem; 2023 Mar; 71(3):131-138. PubMed ID: 36971322
[TBL] [Abstract][Full Text] [Related]
34. Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases.
Deveci MA; Paydaş S; Gönlüşen G; Özkan C; Biçer ÖS; Tekin M
Acta Orthop Traumatol Turc; 2017 Jan; 51(1):1-6. PubMed ID: 27784623
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
[TBL] [Abstract][Full Text] [Related]
36. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
Yonezawa N; Murakami H; Kato S; Takeuchi A; Tsuchiya H
Eur Spine J; 2017 May; 26(Suppl 1):236-242. PubMed ID: 28396950
[TBL] [Abstract][Full Text] [Related]
37. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
38. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study.
Martin-Broto J; Cleeland CS; Glare PA; Engellau J; Skubitz KM; Blum RH; Ganjoo KN; Staddon A; Dominkus M; Feng A; Qian Y; Braun A; Jacobs I; Chung K; Atchison C
Acta Oncol; 2014 Sep; 53(9):1173-9. PubMed ID: 24834795
[TBL] [Abstract][Full Text] [Related]
39. Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone.
Lipplaa A; Dijkstra S; Gelderblom H
Curr Opin Oncol; 2019 Jul; 31(4):329-335. PubMed ID: 30844887
[TBL] [Abstract][Full Text] [Related]
40. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]